Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avexitide (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Eiger BioPharmaceuticals, Inc.

    • Most Recent Events

    • 10 Jul 2024 Results presented in the Amylyx Pharmaceuticals Media Release.
    • 20 Jun 2022 The primary endpoint Incidence of treatment-emergent adverse events was removed, according to ClinicalTrials.gov record.
    • 23 Feb 2021 Results published in the Eiger BioPharmaceuticals, Inc. Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top